Business Wire

Calvin McDonald Joins The Wella Company as CEO

11.2.2026 14:30:00 CET | Business Wire | Press Release

Share

The Wella Company, an innovative global beauty leader, today announced that Calvin McDonald has been chosen as the company’s next Chief Executive Officer, effective April 2, 2026. Calvin will also be appointed to the company’s Board of Directors and will be based in New York. Glenn Murphy will remain as Executive Chair to provide continuity as well as strategic advice to the new CEO and the leadership team.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210093439/en/

Calvin McDonald

“We are delighted to welcome Calvin to The Wella Company,” said Glenn Murphy, Executive Chair. “As a three-time CEO, he brings decades of experience at industry-leading global consumer brands and retail businesses. Calvin’s proven ability to drive results through product differentiation, category expansion, and smart investments will help us win in the dynamic beauty sector.”

Under KKR’s ownership, The Wella Company has been transformed into a global powerhouse of iconic brands that both professionals and consumers trust. The company's robust brand portfolio includes Wella Professionals—the #1 salon color brand globally*, Sebastian Professional, OPI, ghd, Nioxin, and Clairol. Over the past few years, the team has further elevated the brands, refined the innovation pipeline, and built a solid foundation for long-term sustainable growth.

“We are pleased with the growth that Wella has achieved since our initial investment and are confident that Calvin is the right leader to build on that foundation and propel the company into its next chapter,” said Nancy Ford, Partner at KKR. “We thank Glenn for his leadership of The Wella Company and look forward to working with him in his new capacity, alongside Calvin and the broader leadership team as they continue to further Wella’s success and reach in the beauty sector globally.”

“I’m thrilled to return to the beauty industry—an innovative, fast evolving sector powered by consumers who are genuinely passionate about the products they love,” said Calvin McDonald.

Calvin is a recognized leader across multiple portions of the consumer space. As President and CEO of Sephora Americas, a division of the LVMH group of luxury brands, Calvin oversaw five consecutive years of double-digit growth, transformed Sephora into a market leader in the Americas, and grew haircare into the company’s fastest-growing category. He built a strong foundation for innovation, positioning Sephora as an industry pioneer with the ability to anticipate trends and incubate brands to meet evolving consumer needs. Calvin most recently served as CEO of lululemon athletica inc., where he guided the company through a period of significant growth and innovation, more than tripled annual revenues, and broadened global reach to over 30 geographies.

“I’m energized by the opportunity to use my experience to help elevate these iconic brands, partner with the pros who bring them to life, and unlock new ways to connect with consumers,” continued McDonald. “This is a pivotal moment for The Wella Company, and I’m excited to join this talented team as we shape the future of beauty together.”

Calvin is a member of the Board of Directors of The Walt Disney Company. He holds an MBA from the Rotman School of Management at the University of Toronto and a Bachelor of Science degree from the University of Western Ontario.

About Calvin McDonald

Calvin McDonald is a growth-oriented leader with a proven track record of helping large organizations scale, innovate, and elevate customer engagement in stores and across digital channels. In his most recent role as Chief Executive Officer at lululemon athletica inc., Mr. McDonald drove significant growth, tripling the company’s annual revenues over seven years, broadening its global reach to over 30 countries, and expanding the product portfolio to include new athletic and lifestyle categories such as tennis and golf.

Prior to joining lululemon in August 2018, Mr. McDonald served for five years as president and CEO of Sephora Americas, a division of the LVMH group of luxury brands, driving five consecutive years of double-digit growth and turning haircare into the company’s fastest-growing category. Earlier in his career, he held multiple senior roles across some of Canada’s largest retailers, including 17 years at Loblaw Companies Limited.

He earned his MBA from the University of Toronto and Bachelor of Science degree from the University of Western Ontario. Born and raised in Canada, Mr. McDonald is an endurance athlete who frequently competes in ironman distance triathlons and marathons. He and his wife enjoy spending time with their four children.

Mr. McDonald serves on the Board of Directors of The Walt Disney Company.

About The Wella Company

The Wella Company is an innovative global beauty leader with a strategically integrated portfolio of iconic, time-tested hair, nail, and beauty tech brands. The company's robust brand portfolio including Wella Professionals—the #1 salon color brand globally*—along with Sebastian Professional, OPI, ghd, Nioxin, and Clairol, empowers professional hair and nail artists and beauty-loving consumers worldwide.

Built on 145 years of creating legendary beauty, The Wella Company operates through a powerful, digitally led distribution network that reaches customers globally across professional salons, premium retail, mass retail, and eCommerce channels. The company's fusion of science, technology, and artistry produces performance-led products, often distinguished by patented technology and professional expertise.

Working as a connected, diverse global community of 6,000+ employees, we have a shared desire to positively impact the communities we serve. The Wella Company has a performance-based culture, an enduring entrepreneurial spirit, and a compelling vision to enable individuals to look, feel, and be their true selves. The company has primary offices in New York City, Geneva, London, and Calabasas, California.

*Based on Wella Master Brand USD sales on the 2024 Salon Hair Care Global Series for the hair coloring products category published by Kline

View source version on businesswire.com: https://www.businesswire.com/news/home/20260210093439/en/

Contacts

Media Contacts

Alix Dunn
Alix.Dunn@wella.com

FGS Global
wellacompany@fgsglobal.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye